Skip to main content

Table 2 IORT studies for renal cancer

From: Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers

Reference N. pts Type of cancer Primary/recurrent EBRT IORT dose (Gy) Technique Median follow-up Local control Overall survival Toxicity
Paly [27] 98 Advanced or recurrent renal cell carcinoma Pelvic locally recurrent 100% 26 pts: 45–40 Gy pre or post surgery Median dose: 15 Gy (9.5-20 Gy) IORT 3.5-years (3–169) 5-years 39% advanced disease 5-years 52% recurrent disease 5-years 37% advanced disease 5-years 55% recurrent disease NA
Habl [28] 17 Locally recurrent disease Pelvic locally recurrent 100% - Median dose: 15 Gy (10–20 Gy) IORT 18 months 2 years 91% 2 years 73% No late toxicities
Calvo [29] 25 Advanced or recurrent renal cell carcinoma Pelvic locally recurrent 100% 15 pts: 44 Gy perioperative Median dose: 14 Gy (9–15 Gy) IORT 22.2 years (3.6-26) 5-years 80% 5-years 38%
10-year 18%
6 pts acute/late toxicities ≥ 3
Hallemeir
[30]
22 Advanced or recurrent renal cell carcinoma - 21 pts: 41.5 Gy perioperative Median dose: 12.5 Gy (10–20 Gy) IORT 9.9 years (3.6-20) NA 5-years 40% 5 ptsacute/late toxicities ≥ 3
Master [31] 14 Local recurrent renal cell carcinoma Pelvic locally recurrent 100% - Median dose: 15 Gy (12–20 Gy) IORT NA NA 5 years 30% NA
Eble [32] 14 Advanced or recurrent renal cell carcinoma - 14 pts:40 Gy postoperative 15-20 Gy IORT 24.3 months NA 11.5 months 0%
Frydenberg
[33]
11 Local persistence or local recurrent   11 pts: 45–50.4 Gy preoperative 10-25 Gy IORT NA NA NA NA
  1. Pts patients, IORT Intraoperative radiotherapy, IOERT intraoperative electron radiotherapy, EBRT external beam radiotherapy, GU genitourinary, GI gastrointestinal, NA not available